Frequently Asked Questions
Factors such as increased incidence of kidney diseases and rising demand for oral drugs are acting as the major drivers for the global neuraminidase inhibitors market.
The major companies operating in this market are Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), BIOCRYST PHARMACEUTICALS, INC. (U.S.), NATCO Pharma Limited (India).
The major countries covered in the Neuraminidase Inhibitors Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
On the basis of product, the Neuraminidase Inhibitors Market is segmented into Zanamivir, Oseltamivir, Peramivir, Laninamivir, Other.
